TMEM16A inhibitors as a treatment option for cystic fibrosis
TMEM16A inhibitors as a treatment option for cystic fibrosis
- TMEM16A inhibitors represent a causal treatment for cystic fibrosis
- They reduce both excessive mucus formation and airway contraction
- Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs
